Arformoterol
As of the edition of 20 October 2026, Arformoterol is a small molecule: marketed, first approved in 2006 (US); acts on ADRB2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- Brand name
- Brovana
- First approved
- 6 October 2006 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Lupin
- Registered trials
- 17, 4 stopped early
- Disease areas
- Lungs and airways; Infections; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 6 | 5 | 0 | 1 |
| Phase 4 | 7 | 3 | 0 | 3 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lupin | Acquired holder | 2023 to now |